Pulmocide
Developer of antifungal drugs designed to treat acute and chronic respiratory diseases. The company's drugs are specifically designed for inhaled use to maximize the amount of medicine in the lung and...
Valuation
$291.6M
Market implied
Share Price
N/A
Total Raised
$267.6M
Last Round
N/A